(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group. The Sandoz Family Foundation, through the vehicle Emasan AG, is offering 26.5 ...

Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.From today, the ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...

No-moat Sandoz reported solid fourth-quarter earnings that came in largely in line with our expectations. Total sales of $2.7 billion were up 6.7%, or 9% in constant currency, year over year ...

ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal said on ...

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. From February 24, the medicine is commercially available to patients ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nyxoah (NYXH – Research Report), Sandoz Group Ltd (SDZXF – Research Report) and Roche Holding ...

Delpharm also signed a 10-year, long-term supply agreement with Sandoz Canada. BOUCHERVILLE — Delpharm is modernizing its injectable manufacturing facility in Boucherville, Quebec, with the help ...

The notice, dated January 2025, informs Opus Genetics that Sandoz has filed an Abbreviated New Drug Application (ANDA) with the FDA to produce a generic version of RYZUMVI™, a drug currently ...